Amplio Pharma Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
Series A
- (Upcoming)
- Latest Deal Amount
-
$11.5M
- Investors
-
8
Amplio Pharma General Information
Description
Developer of improved versions of existing drugs designed to improve the treatment of rheumatoid arthritis. The company develops a methotrexate-based product that uses proprietary retention technology to increase the amount of methotrexate retained inside immune cells, enabling healthcare professionals to improve patient response rates.
Contact Information
Website
www.amplio-pharma.comCorporate Office
- Hulstweg 11
- 1032 LB Amsterdam
- Netherlands
Corporate Office
- Hulstweg 11
- 1032 LB Amsterdam
- Netherlands
Amplio Pharma Timeline
Amplio Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series A) | $11.5M | Upcoming | Clinical Trials - Phase 1 | |||
| 6. Later Stage VC | 17-Feb-2026 | Completed | Clinical Trials - Phase 1 | |||
| 5. Seed Round | 04-Apr-2025 | Completed | Clinical Trials - Phase 1 | |||
| 4. Seed Round | 11-Mar-2025 | Completed | Clinical Trials - Phase 1 | |||
| 3. Seed Round | 28-Sep-2023 | Completed | Clinical Trials - Phase 1 | |||
| 2. Accelerator/Incubator | Completed | Clinical Trials - Phase 1 | ||||
| 1. Accelerator/Incubator | Completed | Clinical Trials - Phase 1 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Amplio Pharma Patents
Amplio Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3630188-A1 | A pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy | Active | 31-May-2017 | ||
| EP-3630188-B1 | A pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy | Active | 31-May-2017 | ||
| US-20200101074-A1 | A pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy | Active | 31-May-2017 | ||
| ES-2897200-T3 | A pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of the composition in therapy | Active | 31-May-2017 | ||
| US-11883405-B2 | Pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy | Active | 31-May-2017 | A61K31/519 |
Amplio Pharma Signals
Amplio Pharma Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Amsterdam UMC Ventures Holding | Venture Capital | Minority | ||
| ROM InWest | Asset Manager | Minority | ||
| UvA Ventures Holding | Venture Capital | Minority | ||
| Innovatiefonds Noord-Holland | Venture Capital | Minority | ||
| Libertatis Ergo Holding (LEH) | Venture Capital | Minority |
Amplio Pharma FAQs
-
When was Amplio Pharma founded?
Amplio Pharma was founded in 2020.
-
Where is Amplio Pharma headquartered?
Amplio Pharma is headquartered in Amsterdam, Netherlands.
-
What is the size of Amplio Pharma?
Amplio Pharma has 9 total employees.
-
What industry is Amplio Pharma in?
Amplio Pharma’s primary industry is Drug Discovery.
-
Is Amplio Pharma a private or public company?
Amplio Pharma is a Private company.
-
What is Amplio Pharma’s current revenue?
The current revenue for Amplio Pharma is .
-
How much funding has Amplio Pharma raised over time?
Amplio Pharma has raised $2.19M.
-
Who are Amplio Pharma’s investors?
Amsterdam UMC Ventures Holding, ROM InWest, UvA Ventures Holding, Innovatiefonds Noord-Holland, and Libertatis Ergo Holding (LEH) are 5 of 8 investors who have invested in Amplio Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process